Known targets — ChEMBL curated mechanism
PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Tryptophan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.78 |
| ▸ | MAPT | P10636 | 3/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.78 |
| ▸ | LMNA | P02545 | 2/20 | 0.78 |
| ▸ | TSHR | P16473 | 2/20 | 0.78 |
| ▸ | BLM | P54132 | 2/20 | 0.78 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.78 |
| ▸ | MEN1 | O00255 | 2/20 | 0.78 |
| ▸ | MPO | P05164 | 1/20 | 0.78 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.78 |
| ▸ | MC4R | P32245 | 2/20 | 0.61 |
| ▸ | MC5R | P33032 | 1/20 | 0.61 |
| ▸ | MC3R | P41968 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | APAF1 | O14727 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | HTR1A | P08908 | 2/20 | 0.55 |
| ▸ | HTR2A | P28223 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dl-Tryptophan SCHEMBL2255452 | 1.00 | KDM4E (0.78) | KDM4EMAPTKMT2ALMNATSHR | |
| Dl-Tryptophan SCHEMBL30058301 | 1.00 | KDM4E (0.78) | KDM4EMAPTKMT2ALMNATSHR | |
| Tryptophan SCHEMBL3515219 | 1.00 | KDM4E (0.78) | KDM4EMAPTKMT2ALMNATSHR | |
| Dl-Tryptophan SCHEMBL26981429 | 1.00 | KDM4E (0.78) | KDM4EMAPTKMT2ALMNATSHR | |
| Dl-Tryptophan SCHEMBL27153934 | 1.00 | KDM4E (0.78) | KDM4EMAPTKMT2ALMNATSHR | |
| Dl-Tryptophan SCHEMBL27705509 | 0.96 | KDM4E (0.80) | KDM4EMAPTKMT2ALMNATSHR | |
| Dl-Tryptophan SCHEMBL21219049 | 0.95 | KMT2A (0.71) | KDM4EMAPTKMT2ALMNATSHR | |
| Tryptophan SCHEMBL6030686 | 0.94 | KDM4E (0.70) | KDM4EMAPTKMT2ALMNATSHR | |
| Tryptophan SCHEMBL14719809 | 0.92 | KDM4E (0.67) | KDM4EMAPTKMT2ALMNATSHR | |
| Dl-Tryptophan SCHEMBL27584251 | 0.92 | KDM4E (0.67) | KDM4EMAPTKMT2ALMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116773793-A | Streptavidin blocking agent and detection kit | 中元汇吉生物技术股份有限公司 | 2023-09-19 | — | — | CN | claimed |
| WO-2018132876-A1 | NOVEL GLYCINE TRANSPORT INHIBITORS FOR THE TREATMENT OF PAIN | THE UNIVERSITY OF SYDNEY (AU) | 2018-07-26 | — | — | WO | claimed |
| EP-3103446-A2 | PHARMACEUTICAL PREPARATION FOR PREVENTING AND TREATING PROGRESSIVE MYOPIA | Zakharov, Ivan Dmitrievich (RU) | 2016-12-14 | — | — | EP | claimed |
| US-9164106-B2 | Determination of decreased metabolism of tryptophan in diagnosis of autism spectrum disorders | GREENWOOD GENETIC CENTER, INC. (US) | 2015-10-20 | — | — | US | claimed |
| EP-2502933-B1 | METHOD FOR PREPARING GINTONIN, WHICH IS A NOVEL GLYCOLIPOPROTEIN FROM PANAX GINSENG, AND GINTONIN, WHICH IS A NOVEL GLYCOLIPOPROTEIN, PREPARED BY THE METHOD | UNIV KONKUK IND COOP CORP (KR) | 2014-07-02 | — | — | EP | claimed |
| US-20130244273-A1 | Determination of Decreased Metabolism of Tryptophan in Diagnosis of Autism Spectrum Disorders | GREENWOOD GENETIC CENTER, INC. (US) | 2013-09-19 | — | — | US | claimed |
| US-20120282232-A1 | Nutrient Hydration Bar | TOBIN JOHN GEORGE (US) | 2012-11-08 | — | — | US | claimed |
| EP-2502933-A2 | METHOD FOR PREPARING GINTONIN, WHICH IS A NOVEL GLYCOLIPOPROTEIN FROM PANAX GINSENG, AND GINTONIN, WHICH IS A NOVEL GLYCOLIPOPROTEIN, PREPARED BY THE METHOD | Konkuk University Industrial Cooperation Corp. (KR) | 2012-09-26 | — | — | EP | claimed |
| EP-2361602-A2 | A hair building solid agent | Pangaea Laboratories Limited (GB) | 2011-08-31 | — | — | EP | claimed |
| US-20110195039-A1 | HAIR BUILDING SOLID AGENT | PANGAEA LABORATORIES LTD. (GB) | 2011-08-11 | — | — | US | claimed |
| EP-1503737-B1 | NANOPARTICULATE NYSTATIN FORMULATIONS | ELAN PHARMA INT LTD (IE) | 2009-01-07 | — | — | EP | claimed |
| EP-1543032-B1 | METHOD FOR THE RATIONAL MUTAGENESIS OF A/BETA T CELL RECEPTORS AND CORRESPONDINGLY MUTATED MDM2 PROTEIN-SPECIFIC A/BETA T-CELL RECEPTORS | UNIV MAINZ JOHANNES GUTENBERG (DE) | 2009-01-07 | — | — | EP | claimed |
| EP-1292609-A2 | PEPTIDES, COMPOSITIONS AND METHODS FOR THE TREATMENT OF BURKHOLDERIA CEPACIA | HERCULES INCORPORATED (US) | 2003-03-19 | — | — | EP | claimed |
| US-20020051819-A1 | Peptides, compositions and methods for the treatment of burkholderia cepacia | HERCULES INCORPORATED | 2002-05-02 | — | — | US | claimed |
| WO-2001098364-A2 | PEPTIDES, COMPOSITIONS AND METHODS FOR THE TREATMENT OF BURKHOLDERIA CEPACIA | HERCULES INCORPORATED (US) | 2001-12-27 | — | — | WO | claimed |
| CN-117599013-A | Nanometer composition, preparation method and application thereof | 赣州和美药业股份有限公司 | 2024-02-27 | — | — | CN | disclosed |
| EP-3103446-B1 | PHARMACEUTICAL PREPARATION FOR PREVENTING AND TREATING PROGRESSIVE MYOPIA | ZAKHAROV IVAN DMITRIEVICH (RU) | 2024-02-14 | — | — | EP | disclosed |
| WO-1993015731-A1 | PHOSPHATE DERIVATIVES OF VITAMIN E TO PROTECT CELLS FROM EFFECTS OF AGING AND INJURY | LAMB ROBERT (US) | 1993-08-19 | — | — | WO | disclosed |
| US-5051185-A | Cleaning and regeneration of body fluids by adsorption of microglobulins | ASAHI KASEI KOGYO K.K. (JP) | 1991-09-24 | — | — | US | disclosed |
| EP-0319144-A1 | Adsorbent of beta 2-microglobulin | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1989-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020051819-A1 | Peptides, compositions and methods for the treatment of burkholderia cepacia | NGLY1, VIP, CSTB | KDM4E 4776/4885MAPT 4266/4885KMT2A 4667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.